Politics
Federal Officials Announce Plan For ‘Accelerating’ Access To Psychedelics For Patients With Mental Health Conditions Following Trump’s Order
Federal health officials are taking steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions.
Following President Donald Trump’s signing an executive order aimed at expanding and expediting research on the medical benefits of psychedelics, the Food and Drug Administration (FDA) on Friday announced a series of regulatory actions to support the development of psychedelics as approved medications.
“Under President Trump’s leadership, we are accelerating the research, approval, and responsible access to promising mental health treatments—including psychedelic therapies like ibogaine—to confront our nation’s mental health crisis head-on, especially for our veterans,” Health and Human Services Secretary Robert F. Kennedy, Jr. said. “The FDA will prioritize therapies with Breakthrough Therapy designation, where early evidence shows meaningful improvement over existing options for serious mental illness.”
The new steps being announced on Friday include the issuance of national priority vouchers to three companies studying psilocybin for treatment-resistant depression and major depressive disorder, as well as methylone (MDMC) for post-traumatic stress disorder (PTSD).
FDA is also allowing an early phase clinical study of noribogaine hydrochloride to move forward following an Investigational New Drug (IND) submission, with sponsor company DemeRx NB exploring the substance as a potential treatment for alcohol use disorder.
It marks the first time federal officials are allowing a clinical study in the U.S. of a derivative of ibogaine.
“These medications have the potential to address the nation’s mental health crisis, including conditions like treatment-resistant depression, alcoholism and other serious mental health and substance abuse conditions,” FDA Commissioner Marty Makary said. “As this field moves forward, it is critical that their development is grounded in sound science and rigorous clinical evidence. We owe it to our nation’s veterans and all Americans who are suffering from these conditions to evaluate these potential therapies with urgency.”
The agency additionally says it will soon be releasing guidance providing recommendations to sponsors developing psychedelic medicines.
The psychedelic research guidance will include recommendations on study design, data collection and generation, patient monitoring and conducting adequate and well-controlled clinical investigations.
“There is a growing recognition of the potential of psychedelic medications to address multiple different psychiatric conditions that are notoriously difficult to treat,” Tracy Beth Hoeg, acting director FDA’s Center for Drug Evaluation and Research, said. “At the FDA we are showing our support of investigating the safety and efficacy of this class of drugs through today’s actions.”
Trump said when he signed the executive order last weekend that it will “dramatically accelerate access to new medical research and treatments based on psychedelic drugs,” Trump said. “In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression—including our cherished veterans.”
Steps taken under the order will “clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA and the Department of Veterans Affairs, and facilitate fast rescheduling of any psychedelic drugs that become FDA approved,” the president said.
Some psychedelics like psilocybin and MDMA have been designated with “breakthrough therapy” status, meaning that preliminary clinical evidence shows they can provide substantial improvement over existing therapies. Trump said his order will “expedite” the further review of such substances.
The president also announced that the federal government is making $50 million available to support state-level research on ibogaine and is “opening a pathway for the substance to be administered to desperately ill patients under the Right to Try law” that he signed during his first term in office.
Under Trump’s order, health officials will coordinate with the Drug Enforcement Administration (DEA) and Department of Justice on rescheduling reviews for psychedelics that complete successful Phase 3 trials.
A growing body of research and experience indicates that psychedelics can help people suffering with post-traumatic stress disorder, traumatic brain injuries, drug addiction and other mental health disorders.
Lawmakers in a number of states have passed legislation to support clinical trials with the aim of developing ibogaine into a legal medication with approval from the Food and Drug Administration (FDA).
Texas officials, for example, recently announced that the state will move ahead with launching its own research program on the psychedelic after the they couldn’t find a company to lead a consortium on the issue under a bill enacted last year.
Meanwhile, Kennedy said recently that the Trump administration is “very anxious” to create a pathway for access to psychedelics therapy and that top officials across federal agencies want to “get it out to the public as quickly as possible.”
In an interview on the Joe Rogan Experience in February, Kennedy said he’s confident “we’re going to get it done,” with plans to develop and finalize rules that would enable patients with conditions such as post-traumatic stress disorder (PTSD) and depression to access psychedelic substances like psilocybin and MDMA in a “very controlled setting.”
“Everybody in my agency…is very anxious to get a rule out there that will allow these kind of studies and will allow access under therapeutic settings, particularly [for] the military soldiers who have suffered these injuries to get access to these products,” the HHS secretary said. “We’re working through that process now. We’re all working on it and trying to make it happen.”
“I think that we’re going to get it done,” he said.
Last June, Kennedy said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.”
Veterans Affairs Secretary Doug Collins also disclosed in April that he had an “eye-opening” talk with Kennedy about the therapeutic potential of psychedelic medicine. And he said he’s open to the idea of having the government provide vouchers to cover the costs of psychedelic therapy for veterans who receive services outside of VA as Congress considers pathways for access.
Bipartisan congressional lawmakers introduced legislation this session to provide $30 million in funding annually to establish psychedelic-focused “centers for excellence” at U.S. Department of Veterans Affairs (VA) facilities, where veterans could receive novel treatment involving substances like psilocybin, MDMA and ibogaine.
A U.S. Senate committee has scheduled a hearing for next week on a bipartisan bill to promote research into the therapeutic potential psychedelics by creating a new office at VA that would advance the development innovative treatments for serious mental health conditions and assist in reviewing the scheduling status of drugs like psilocybin, ibogaine and MDMA.
Former U.S. House Speaker Newt Gingrich (R-GA) has said ibogaine represents an “astonishing breakthrough” in the nation’s current “sick care system” that’s left people with serious mental health conditions without access to promising alternative treatment options.
Photo courtesy of Wikimedia/Mushroom Observer.
